Shanghai Junshi Biosciences Co., Ltd. (01877.HK)価格

Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,578 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The firm's main businesses are the discovery, clinical research and development of innovative drugs. The firm's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The firm is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The firm provides its products for domestic and overseas markets.